Lake Street lowered the firm’s price target on Biodesix (BDSX) to $2 from $3 and keeps a Buy rating on the shares after the company reported Q1 revenue short of the firm’s estimate and consensus and reduced 2025 revenue guidance to $80M-$85M from $92M-$95M. Following the report, the firm reduced its price target to reflect multiple compression and near-term uncertainty surrounding the implementation of the new sales infrastructure.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDSX: